أرسل هذا في رسالة قصيرة: Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials

  _  __     ___       _____    ______  __    __  
 | |/ //   / _ \\    / ___//  /_   _// \ \\ / // 
 | ' //   / //\ \\   \___ \\   -| ||-   \ \/ //  
 | . \\  |  ___  ||  /    //   _| ||_    \  //   
 |_|\_\\ |_||  |_|| /____//   /_____//    \//    
 `-` --` `-`   `-` `-----`    `-----`      `